Lantern Pharma Inc. reported a net loss of approximately $10.4 million for the six months ended June 30, 2026, compared to a loss of about $8.9 million for the same period in 2025. The company's total operating expenses decreased to $6.9 million from $9.4 million year-over-year, primarily due to a significant reduction in research and development costs, which fell to $3.5 million from $6.3 million. General and administrative expenses increased slightly to $3.4 million from $3.1 million, reflecting higher business development and investor relations expenditures.
The company’s financial position showed a decline in total assets, which decreased to approximately $8.6 million as of June 30, 2026, down from $11.0 million at the end of 2025. Cash and cash equivalents increased to $6.7 million from $4.4 million, bolstered by a registered direct offering in May 2026 that generated gross proceeds of about $4.4 million. However, Lantern Pharma's liabilities surged to $11.8 million, primarily due to the establishment of a warrant liability of $7.5 million following the issuance of warrants in connection with the offering.
Strategically, Lantern Pharma formed a new subsidiary, Open Medicine AI Inc., in July 2026, aimed at commercializing its AI platform, withZeta.ai. This move is expected to enhance funding opportunities and potentially lead to a separate valuation for the AI business. The company anticipates that Open Medicine AI will expand into additional disease areas and modalities, leveraging its multi-agent AI co-scientist platform. Lantern Pharma's ongoing clinical programs include three lead drug candidates—LP-300, LP-184, and LP-284—targeting various cancer indications, with LP-300 currently in a Phase 2 trial.
Operationally, Lantern Pharma's research and development expenses have fluctuated significantly, reflecting the company's focus on advancing its clinical trials. The company reported a decrease in research expenses related to its lead candidates, with LP-300, LP-184, and LP-284 collectively accounting for $3.0 million in costs for the first half of 2026. The company continues to face substantial challenges in securing additional funding, raising concerns about its ability to sustain operations over the next 12 months without further capital raises. The outlook remains cautious, with management indicating that ongoing losses are expected as the company continues to invest in its drug development pipeline.
About Lantern Pharma Inc.
Lantern Pharma Inc. is an AI-driven biopharmaceutical company focused on developing targeted cancer therapies. Its proprietary RADR platform analyzes vast genomic and clinical data to identify and rescue promising drug candidates, including small molecules and antibody-drug conjugates. The company targets oncology markets with personalized, biomarker-driven treatments, leveraging data science to accelerate drug discovery, reduce costs, and improve patient outcomes in solid tumors and blood cancers.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov